Оценка эффективности и оптимизация дезаггрегантной терапии при эндоваскулярном лечении у больных с ИБС
Диссертация
Как известно, в 80-е годы интервенционные кардиологи предложили лечение однососудистых поражений коронарных артерий с помощью технологии на катетерной основе. Но вскоре подобная методика была распространена на больных с множественным поражением коронарных артерий, на неблагоприятные формы поражения коронарных артерий и пораженные венозные трансплантаты. Это сразу усилило тенденции в лечении… Читать ещё >
Список литературы
- Аверков О. В. Клопидогрель: новые стандарты антитромбоцитарной терапии при внутрикоронарных вмешательствах и возможные перспективы использования. // Фарматека: Международный медицинский журнал. 2003. — N 3. — С. 36−43.
- Акчурин Р.С., Ширяев А. А. Актуальные проблемы коронарной хирургии. // Москва, 2004. С. 34 — 56.
- Алекян Б. Г., Бузиашвили Ю. И., Голухова Е. 3., Никитина Т. Г., Стаферов А. В., Захаров И. В., Янус В. М. Стентирование коронарных артерий в лечении больных ишемической болезнью сердца. // Грудная и сердечно-сосудистая хирургия. 1999. № 6. С. 143-152.
- Беленков Ю.Н., Акчурин Р. С., Савченко А. П., Ширяев А. А., Руденко Б. А. Результаты коронарного стентирования и хирургического лечения у больных ИБС с многососудистым поражением коронарного русла // Кардиология. —2002
- Белов Ю.В. Реконструктивная хирургия при ишемической болезни сердца: Автореф. дис.. д-ра мед. наук. М., 1987. -№ 5
- Беленков Ю.Н., Акчурин Р. С., Савченко А. П., Ширяев А. А., Руденко Б. А. Результаты коронарного стентирования и хирургического лечения у больных ИБС с многососудистым поражением коронарного русла // Кардиология. -2002. —№ 5.
- Бокерия JI.A., Беришвили И. И., Сигаев И. Ю. Минимально инвазивная реваскуляризация миокарда // Москва: Издательство НЦ ССХ им. А. Н. Бакулева РАМН. 2001.
- Бокерия Л.А., Алекян Б. Г., Коломбо А., Бузиашвили Ю. И. Интервенционные методы лечения ишемической болезни сердца // Москва: Издательство НЦ ССХ им. А. Н. Бакулева РАМН. 2002.С. 284−301
- Буза В.В., Карпов Ю. А., Левицкий И. В., Лопухова В. В., Самко А. Н. Отдаленные результаты коронарного стентирования: роль антиагрегантной терапии.// Русский Медицинский Журнал. Кардиология 2008, том 16, № 21.
- Волков В.И., Рябуха В. В., Запровальная О. Е., Ладный А. И. Диагностика резистентности к аспирину у больных с ишемической болезнью сердца. // Украинский кардиологический журнал. — 2006. — № 3. И.
- Джаши В.В. Резистентность к аспирину: обзор современных представлений о возможных механизмах. // Bulletin of the International Scientific Surgical Association 2007.- N. 2−3,Vol.2.
- Карпов Ю.А., Сорокин E.B. Медикаментозное лечение стенокардии: надежды и разочарования.// Русский медицинский журнал. 2009. Том 17, № 18. Кардиология
- Куликов А.Н. Фармакотерапия острых коронарных синдромов. // «ФАРМиндекс-Практик» № 8. 2005. Стр. 3−11
- Мазуров А.В. Антагонисты гликопротеинов Ilb-IIIa при остром коронарном синдроме.// Болезни сердца и сосудов № 4- 2008
- Маслова Н.Ф. Клопидогрель (плавике) современное антиагрегантное средство: доказанная фармакологическая эффективность, //журнал Провизор 2007- № 20.
- Мельниченко Г. А., Пышкина Е. А. Ожирение и инсулинорезистентность — факторы риска и составная часть метаболического синдрома. Тер архив 2001- № 12:5−8.
- Полонский В.М. Клопидогрель: эффективное средство профилактики ишемических нарушений у больных атеросклерозом. Фарматека № 9−10 (51)2001.
- Abciximab in patients with acute coronary syndromes undergoing percutaneus coronary intervention after clopidogrel pretreatment The ISAR-REACT-2 Randomized trial. JAMA 2006- 13.
- Agah R, Plow EF, Topol EJ. allbb3 (GP Ilb-IIIa) antagonists. Platelets. Second Edition. Ed. A. D.Michelson. Elsevier Inc (Amsterdam) 2007: 114 564.
- Ageno W, Prandoni P, Romualdi E, et al. The metabolic syndrome and the risk of venous thrombosis. A case control study. J Thromb Haemost 2006−4:1914−8.
- Ahmad S.S., London F.S., Walsh P.N. The assembly of the factor X-activating complex on activated human platelets. J. Thromb. Haemost., 2003- 1:48−59
- Ahmad S.S., London F.S., Walsh P.N. Bindings studies of the enzyme (factor XIa) with the cofactor (factor VIII) in the assembly of factor-X activating complex on the activated platelet surface. J. Thromb. Haemost., 2003- 1:2348−2355
- Ahmad S.S., Rawala-Sheikh R., Walsh P.N. Comparative interactions of factor IX and factor IXa with human platelets. J. Biol. Chem., 1989- 264: 3244−3251
- Ahmad S.S., Rawala-Sheikh R., Walsh P.N. Plat, elet receptor occupancy with factor IXa promotes factor X activation. J. Biol. Chem., 1989- 264: 20 012−20 016.
- Ahmad S.S., Rawala R., Cheung W.F. et al. The role of the second growth-factor domain of human factor IXa in bindings to platelets and in factor-X activation. Biochem. J., 1995- 310: 427−431
- Ahmad S.S., Rawala-Sheikh R., Ashby B. et al. Platelet receptor-mediated factor X activation by factor IXa. High-affinity factor IXa receptors induced by factor VIII are deficient on platelets in Scott syndrome. J. Clin. Invest., 1989- 84:824−828
- Ahmad S.S., Rawala-Sheikh R., Cheung W.F. et al. High-affinity, specific factor IXa binding to platelets is mediated in part by residues 3−11. Biochemistry, 1994- 33: 12 048−12 055.
- Ahmad S.S., Rawala-Sheikh R., Cheung W.F. et al. The role of the first growth factor domain of human factor IXa in binding to platelets and in factor X activation. J. Biol. Chem., 1992- 267: 8571−8576.
- Ahmad S.S., Rawala-Sheikh R., Monroe D.M. et al. Comparative platelet binding and kinetic studies with normal and variant factor IX molecules. J. Biol. Chem., 1990- 265: 20 907−20 911.
- Ahmad S.S., Scandura J.M., Walsh P.N. Structural and functional characterization of platelet receptor-mediated factor VIII binding. J. Biol. Chem., 2000- 275: 13 071−13 081.
- Ahmad S.S., Walsh P.N. Coordinate binding studies of the substrate (factor X) with the cofactor (factor VIII) in the assembly of the factor X activating complex on the activated platelet surface. Biochemistry, 2002- 41: 1 126 911 276.
- Anderson JL, Home BD, Jones HU, et al. Intermountain Heart Collaborative (IHC) Study Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease? Cardiology. 2004−101:185−193.
- Ay C, Tengler T, Vormittag R, Simanek R, et al. Venous thromboembolism a manifestation of the metabolic syndrome. Haematologica 2007−92:373−9.
- Baglia F.A., BadellinoK.O., Li C.Q. et al. Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J. Biol. Chem., 2002- 277: 1662−1668.
- Baglia F.A., Shrimpton C.N., Lopez J.A. et al. The glycoprotein Ib-IX-V complex mediates localization of factor XI to lipid rafts on the platelet membrane. J. Biol. Chem., 2002- 277: 1662−1668.
- Baglia F.A., Jameson В.A., Walsh P.N. Identification and characterization of a binding site for platelets in the apple 3 domain of coagulation factor XI. J.Biol. Chem., 1995- 270: 6734−6740
- Baglia F.A., Seaman F.S., Walsh P.N. The Apple 1 and Apple 4 domains of factor XI act synergistically to promote the surface-mediated activation of factor XI by factor Xlla. Blood, 1995- 85: 2078−2083.
- Berridge M.J. Inositol triphosphate and diacylglycerol: two interacting second messengers. Annu Rev. Biochem., 1987- 56: 159−193
- Birembaut P., Legrand H.Y., Bariety J. et al. Histochemical and ultrastructural characterization of subendothelial glycoprotein microfibrils interacting with platelets. J. Histochem. Cytochem., 1982- 30: 75−80
- Bock S.C. Antithrombin III and heparin cofactor II. In: Colman R.W., Hirsh J., Marder V.J. et al., eds. Hemostasis and thrombosis: basic principles andiLclinical practice, 4 ed., chap. 16. Philadelphia, PA: Lippincott Williams&Wilkins, 2001:321−365
- Bouchard B.A., Catcher C.S., Trash B.R. et al. Effector cell protease receptorl, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. J. Biol. Chem., 1997- 272: 9244−9251
- Calabro P, Chang DW, Willerson JT, Yeh ET. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005−46:1112−1113.
- Cambia-Kiely J.A., Gandhi P.J. Possible mechanism of aspirin resistance // J. Thromb. Thrombolysis. 2002. — Vol. 13. — P. 49−56.
- Caplain H, Donat F, Gaud C, et al. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999−25(suppl. 2):25−8.
- Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999−25 Suppl 2:25−8.
- Catalano P. M., NMS Hematology, USA, 2008
- Catella-Lawson F., Crofford L.J. Cyclooxygenase inhibition and thrombogenicity // Amer. J. Med. 2001. — Vol. 110. — P. 28−32.
- Celik T, Turhan H, Kursaklioglu H, et al. Impact of metabolic syndrome on myocardial perfusion grade after primary percutaneous coronary intervention in patients with acute ST elevation myocardial infarction. Coron Artery Dis. 2006 May- 17(4):339−43.
- Chan AW, Moliterno DJ, Berger PB, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the TARGET. J Am Coll Cardiol 2003−42: 1188−95.
- Cipollone F, Marini M, Fazia M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vase Biol. 2001−21:327−334.
- Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // Brit. Med. J. 2002. — Vol. 324. — P. 71−86.
- Coller BS. Anti-GPIIb/IIIa drugs: Current strategies and future directions. Thromb Haemost 2001- 86: 427−43.
- Coukell AJ, Markham A. Clopidogrel. Drugs. 1997 Nov-54(5):745−50
- Cutler L., Rodan G., Feinstein M.B. Cytochemical localization of adenylate cyclase and of calcium ion, magnesium ion-activated ATPases in the dense tubular system of human blood platelets. Biochim. Biophys. Acta, 1978- 542: 357−371
- Dahlback В., Stenflo J. Binding of bovine coagulation factor Xa to platelets. Biochemistry, 1978- 17: 4938−4945.
- Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA, May 13, 1998—Vol 279, No. 18.
- Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996−334:952−957.
- Ehara S, Ueda M, Naruko T, Haze K, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001−103:1955−1960.
- Eikelboom, J.W., Hirsh J., Weitz J.I. et al. Aspirin Resistance Aspirin Resistance Response // Circulation. 2002. — Vol. 106. — P. 200−201.
- Fox J.E., Boyles J.K., Reynolds C.C., Phillips D.R. Actin filament content and organization in unstimulated platelets. J. Cell. Biol., 1984- 98: 19 851 991
- Fox J.E. The platelet cytoskeleton. Thromb. Haemost., 1993- 70: 884−893.
- Fuvel F., Grant M.E., Legrand Y.J. et al. Interaction of blood platelets with a microfibrillar extract from adult bovine aorta: requirement for von Willebrand factor. Proc. Natl. Acad. Sci USA., 1983- 80: 551−554
- George J.N. Studies on platelet plasma membranes. IV. Quantitative analysis of platelet membrane glycoproteins by (125J)-diazotized diiodosulfanilic acid labeling and SDS-polycrylamide gel electrophoresis. J. Lab. Clin. Med., 1978: 92: 430−446
- George JN. Platelets. Lancet 2000−355:1531−9.
- Greengard J.S., Heeb M.J., Ersdal E. et al. Binding of coagulation factor XI to washed human platelets. Biochemistry, 1986- 25: 3884−3890.
- Gum P.A., Kottke-Marchant K., Welsh P.A. et al. A prospective, blinded determination of the natural history of aspirin resistance among stablepatients with cardiovascular disease // J. Amer. Coll. Cardiology. 2003. — Vol. 41.-P. 961−965.
- Gu Y.J., Mariani M.A., van Oeveren W, et al. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Ann. Thorac. Surg., 1998, 65: 420−424.
- Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005 May 3−45(9): 1392−6.
- Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets. 2004 Mar-15(2):95−9
- Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 2003−108:1541−1545.
- Feld H., Lichstein E., Schachter J. Early and late angiographic findungs of no-reflow phenomenon following direct angioplasty as primary treatment for acute myocardial infarction. Am Heart J 1992- 123: 782−784
- Haffner S. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol. 2003−92:18J-26J.
- Hake U. Total revascularization of the beating heart: A case study // Trends in Card. Surg. 1999. — Vol. 2. — P. 1−3.
- Hellems H.K., Haynes F.W., Dexter L. Pulmonary capillary pressure in man. J. Appl. Physiol., 1949- 2: 24
- H0 D.H., Baglia F.A., Walsh P.N. Factor XI binding to activated platelets is mediated by residues R (250), К (255), F (260) and Q (263) within the Apple 3 domain. Biochemistry, 200- 39: 316−323
- Ho D.H., Badellino K., Baglia F.A. et al. The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface. J. Biol. Chem., 2000- 275: 25 139−25 145.
- Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005 May 24- 111(20):2560−4.
- Isomaa, В., Lahti, К., Almengren, P. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001), 683−689.
- Jabs WJ, Theissing E, Nitschke M, Bechtel JF, et al. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 2003−108:1428−1431.
- Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000−60:347−77.
- Kane W.H., Majerus P.W. The interaction of human coagulation factor Va with platelets. J. Biol. Chem., 1982- 257: 3963−3969.
- Kasai T, Miyauchi K, Kurata T, et al. Prognostic value of the metabolic syndrome for long-term outcomes in patients undergoing percutaneous coronary intervention. Circ J 2006 Dec-70 (12):1531−7.
- Kasai T, Miyauchi K, Kurata T, et al. Prognostic value of the metabolic syndrome for long-term outcomes in patients undergoing percutaneous coronary intervention. Circ J 2006 Dec-70 (12):1531−7.
- Kaseer-Glanzmann R., Jakabove M., George J.N., Luscher E.F. Further characterization of calcium-accumulating vesicles from human blood platelets. Biochim. Biophys. Acta, 1978- 512: 1−12
- Koenig W. Fibrinogen in cardiovascular disease: an update. Thromb Haemost 2003−89:601−609. — McDonagh J, Lee MH. How does hyperfibrinogenemia lead to thrombosis? Fibrinol Proteol 1997- 1 l (Suppl 1): 13—17.
- Lacoste L, Lam JYT, Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995−92:3172−3177.
- London F.S., Walsh P.N. Zymogen factor IX potentiates factor IXa-catalyzed factor X activation. Biochemistry, 2000- 39: 9850−9858
- Longstreth KL, Wertz JR. High-dose clopidogrel loading in percutaneous coronary intervention. Ann Pharmacother. 2005 May -3 9(5):918—22.
- Magliano DJ, Shaw JE, Zimmet PZ. How to best define the metabolic syndrome. Ann Med 2006- 38 (1): 34−41.
- Mann K.G., Nesheim M.E., Church W.R., hale R., Krishnaswamy S. Surface-dependent relations of the vitamin K-dependent enzyme complexes. Blood, 1990- 76: 1−16
- Marcucci R, Prisco D, Brunelli T et al. Tissue factor and homocysteine levels in ischemic heart disease are associated with angiographically documented clinical recurrences after coronary angioplasty. Thromb Haemost2000- 83: 826—32.
- Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis. J Biol Chem 2002−277:37 487−37 491.
- McEver R.P. Adhesive interactions of leukocytes, platelets and the vessel wall during hemostasis and inflammation. Thromb. Haemost., 2001- 86: 746−756
- Mehilli J, Kastrati A, Schuhlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004- 110: 3627−35
- Mieltich J.P., Jackson C.M., Majerus P.W. Interaction of coagulation factor Xa with human platelets. Proc. Natl. Acad. Sci USA, 1977- 74: 40 334 036.
- Mieltich J.P., Jackson C.M., Majerus P.W. Properties of the factor Xa binding site on human platelets. J. Biol. Chem., 1978- 253: 6908−6916.
- Mieltich J.P., Kane W.H., Hofmann S.L. et al. Deficiency of factor Xa factor Va binding sites on the platelets of a patient with a bleeding disorder. Blood, 1979- 54: 1015−1022.
- Mieltich J.P., Majerus D.W., Majerus P.W. Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets. J. Clin. Invest., 1978- 62: 824−831.
- Pache J, Kastrati A, Mehith J, et al. Clopidogrel therapy in patients undergoing coronary stending: value of high-loading-dose regimen. Cathet Cardiovasc Int 2002−55:436−41 122. PackhamM.A., 1991
- Patti G, Colonna G et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from ARMYDA-2. Circulation 2005- 111: 2099−106.
- Piatti PM, Colombo A Di Mario C, et al. Association of Insulin Resistance, Hyperleptinemia, and Impaired Nitric Oxide Release With In-Stent Restenosis in Patients Undergoing Coronary Stenting. Circulation 2003- 108: 2074−81.
- Phillips D.R., Agin P.P. Platelet plasma membrane glycoproteins. Evidence for the presence of none-equivalent disulfide bonds using nonreduced-reduced two-dimensional del electrophoresis. J. Biol. Chem., 1977- 252: 2121−2126
- Pizzo S.V., Wu S.M. Alpha-macroglobulins and kinins. In: Colman R.W., Hirsh J., Marder V.J. et al., eds. Hemostasis and thrombosis: basiclbprinciples and clinical practice, 4 ed., chap.19 Philadelphia, PA: Lippincott Williams&Wilkins, 2001: 367−379
- Plow E.F., Ginsberg M. The molecular basis of platelet function. In: Hoffman R., Benz E.J., Shaltil S.J., Furie В., Cohen H.J. (eds) Hematology. Basic Principles and Practice. Churchill Livingston, New York, 1991, p. 1165
- Prandoni P, Bilora Trovati M, et al. Impaired insulin induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995−44:1318−22.
- Quinn MJ, Byzova TV, Qin J et al. Integrin allbb3 and its antagonism. Arterioscler Thromb Vase Biol 2003- 23: 388−96.
- Quinn MJ, Fitzgerald DJ. Ticlodipine and clopidogrel. Circulation 1999−100:1667−72.- Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998−114(suppl.):470S-88S.
- Quinn MJ, Fitzgerald DJ. Ticlodipine and clopidogrel. Circulation 1999−100:1667−72.
- Rao S.V., Donahue M., Pi-Sunyer F.X., Fuster V. Obesity as a risk factor in coronary artery disease. Am Heart J 2001- 142: 1002−1007.
- Rawala-Sheikh R., Ahmad S.S., Ashby B. et al. Kinetics of coagulation factor X activation by platelet-bound factor Ixa. Biochemistry, 1990- 29:2606−2611
- Rawala-Sheikh R., Ahmad S.S., Monroe D.M. et al. Role of gammacarboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation. Blood, 1992- 79: 398−405
- Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003−107: 391−397.
- Rink T.J., Sage S.O. Calcium signaling in human platelets. Annu Rev. Physiol., 1990- 52:431−449
- Roth G.J. Platelets and blood vessels: the adhesion event. Immunol. Today, 1992- 13: 100−105
- Rothenbacher D, Brenner H, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005−26:1640−1646.
- Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003−108:414−419.
- Scandura J.M., Ahmad S.S., Walsh P.N. A binding site expressed on the surface of activated human platelets is shared by factor X and prothrombin. Biochemistry, 1996- 35: 8890−8902
- Scandura J.M., Walsh P.N. Factor X bound to the surface of activated human platelets is preferentially activated by platelet-bound factor IXa. Biochemistry, 1996- 35: 8903−8913.
- Schnyder G, Roffi M, Flammer Y et al. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J 2002- 23:726−33.
- Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001- 345 (22): 1593−600.
- Schomig A, Schmitt С et al. One year outcomes with abciximab vs placebo during percutaneus coronary intervention after pre-treatment with clopidogrel. Eur Heart J 2005- 26: 1379−84.
- Scrutton MC, Ross-Murphy SB, Bennett GM, et al. Changes in clot deformability—a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinolysis 1994−5:719−723.
- Serebruany V, Shalito I, Kopyleva O. Prasugrel development claims and achievements. Thromb Haemost. 2009 Jan- 101(1): 14−22.
- Shechter M, Merz N B, Paul-Labrador M J., Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol, 2000- 35:300−307.
- Sinha D., Seaman F.S., Koshy A. et al. Blood coagulation factor Xia binds specifically to a site on activated human platelets distinct from that for factor XI. J. Clin. Invest., 1984- 73: 1550−1556.
- Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007 Aug- 154(2):221−31.
- Stern M. Epidemiology of obesity and its link to heart disease. Metabolism 1995- 44, 9 (suppl. 3): 1−3.
- Sun M.F., Baglia F.A., Ho D. et al. Defective binding of factor XI-N248 to activated human platelets. Blood, 2001- 98: 125−129.
- Takagi T, Akasaka T, Yamamuro A, et al. Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation. Intravascular ultrasound studies. J Diabetes Complications. 2002−16:50−55.
- Theroux P., Quimet H., McCausI. et al. // New Engl. J. Med. — 1988. —V.319. — P. 1105 — 1112.
- Theroux P., Watere D., Lam J. et al. // New Engl: J. Med. —1992. — V. 327.—P. 141 —145.
- Theroux P., Watere D., Qiu S. et al. // Circulation. — 1993.— V. 88. — P. 2045 — 2048.
- Tracy P.B. Regulation of thrombin generation at cell surfaces. Semin. Thromb. Hemost., 1988- 14: 227−233
- Tracy P.B., Eide L.L., Mann K.G. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J. Biol. Chem., 1985- 260: 2119−2124.
- Tracy P.B., Nesheim M.E., Mann K.G. Coordinate binding of factor Va and factor Xa to the unstimulated platelet. J. Biol. Chem., 1981- 256: 743−751.
- Tracy P.B., Nesheim M.E., Mann K.G. Platelet factor Xa receptor. Methods Enzymol., 1992- 215: 329−360.
- Tracy P.B., Peterson J.M., Nesheim M.E. et al. Interaction of coagulation factor V and factor Va with platelets. J. Biol. Chem., 1979- 254: 10 354−10 361.
- Tracy P.B., Mann K.G. Prothrombinase complex assembly on the platelet surface is mediated through the 74,00-dalton component of factor Va. Proc. Natl. Acad. Sci USA, 1983- 80: 2380−2384.
- Tracy P.B., Nesheim M.E., Mann K.G. Proteolytic alterations of factor Va bound to platelets. J. Biol. Chem., 1983- 258: 662−669.
- Walsh P.N. Factor XI. In: Colman R.W., Hirsh J., Marder V.J. et al., eds. Hemostasis and thrombosis: basic principles and clinical practice, 4th ed., chap. 11 Philadelphia, PA: Lippincott Williams&Wilkins, 2001: 191 202.
- Walsh P.N. Platelet coagulant activities and hemostasis: a hypothesis. Blood, 1974- 43: 597−605.
- Walsh P.N. Roles of factor XI, platelets and tissue factor-initiated blood coagulation. J. Thromb. Hemost., 2003- 1: 2081−2086
- Weber AA, Braun M, Hohlfeld T, et al. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol. 2001 Sep-52(3):333−6.
- Weiss H.J. Platelet physiology and abnormalities of platelet function (first of two parts). N. Engl. J. Med., 1975- 293: 531−541
- White J.G. Effects of colchicine and Vinca alkaloids on human platelets. I. Influence on platelet microtubules and contractile function. Am. J. Pathol., 1968- 53:281−291
- White J.G. Electron microscopic studies of platelet secretion. Progr. Hemost. Thromb., 1974- 2: 49−98
- White J.G. Identification of platelet secretion in the electron microscope. Ser. Haematol., 1973- 6: 429−459
- White J.G. Platelet ultrastructure. In: Bloom A.L., Thomas D.P. (eds) Haemostasis and Thrombosis, 2nd ed. Churchill Livingston, Edindurg, 1987, p.20
- White J.G. The submembrane filaments of blood platelets. Am. J. Pathol., 1969- 56: 267−277
- Wilkinson F.H., Ahmad S.S., Walsh P.N. The factor IXa second epidermal growth factor (EGF2) domain mediates platelet binding and assembly of the factor X activating complex. J. Biol. Chem, 2002- 277: 5734−5741.
- Wilkinson F.H., London F.S., Walsh P.N. Residues 88−109 of factor IXa are important for assembly of the fator-X activating complex. J. Biol. Chem, 2002- 277: 5725−5733.
- Wilson JM, Ferguson III JJ. Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications. Clin Cardiol 1999−22:687−98.
- Yee D.L., Sun C.W., Bergeron A.L., Dong J.F., Bray P.F. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood, 2005- 106: 2723−2729
- Zucker-Franklin D. The submembranous fibrils of human blood platelets. J. Cell Biol., 1970- 47: 293−299